[ { "id": 1551, "name": "Indee Labs", "slug": "indee-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ac1b20e8e540ce71927b19ed6cbc32f9956f9290.png", "website": "http://www.indeelabs.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.", "one_liner": "Enabling T cell immunotherapy discovery, development and manufacturing", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1481766629, "tags": [ "Gene Therapy", "Microfluidics", "Cell Therapy" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/indee-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/indee-labs.json", "year_founded": 2015, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/indee-/", "x_url": "https://twitter.com/indeelabs", "fb_url": "https://www.facebook.com/indeelabs/", "cb_url": "https://www.crunchbase.com/organization/indee-2", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ac1b20e8e540ce71927b19ed6cbc32f9956f9290.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 168592, "full_name": "Ryan Pawell", "title": "Founder/CEO", "founder_bio": "My career aim is to use technology to improve health outcomes. See more on my LinkedIn profile.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/rpawell", "x_url": "https://twitter.com/rpawell", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1ec7eb2c05b850d36f6c41f641ae037e721c12d5.jpg" } ], "jobs": [], "news": [ { "title": "Indee Labs Announces Strategic Investment from BroadOak BioTools Venture Fund", "url": "https://www.prnewswire.com/news-releases/indee-labs-announces-strategic-investment-from-broadoak-biotools-venture-fund-301794866.html", "date": "Apr 12, 2023" }, { "title": "Indee Labs Awarded $2M Contract to Scale up and out Hydropore for Cell Therapy — Indee Labs", "url": "https://www.indeelabs.com/news/indee-labs-awarded-2m-contract-to-scale-up-and-out-hydropore-for-cell-therapy", "date": "Nov 02, 2022" } ], "launches": [] }, { "id": 11979, "name": "LEAH Labs", "slug": "leah-labs", "former_names": [ "Lifengine Animal Health Laboratories", "Incorporated" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6907f0370b96042be3d0036ddc25c34015a02b50.png", "website": "http://www.leahlabs.com", "all_locations": "Minneapolis, MN, USA", "long_description": "LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective \"full stack\" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation. ", "one_liner": "Living therapies for pets first, and their people next", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541131379, "tags": [ "CRISPR", "Cell Therapy", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/leah-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/leah-labs.json", "year_founded": 2018, "city": "Minneapolis", "country": "US", "linkedin_url": "http://www.twitter.com/leahlabsincwww.linkedin.com/leahlabsinc", "x_url": "http://www.twitter.com/leahlabsinc", "fb_url": "http://www.facebook.com/leahlabsinc", "cb_url": "https://www.crunchbase.com/organization/leah-labs", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/6907f0370b96042be3d0036ddc25c34015a02b50.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 262103, "full_name": "Wesley Wierson", "title": "Founder", "founder_bio": "I am a scientist and entrepreneur applying my expertise in gene editing towards solving consumer level problems in society, first focused on building curative cancer therapies for pets, and eventually their owners. \n\nThrough my time at LEAH Labs, I've also found a passion for biotech business model innovation through regulatory arbitrage - e.g. CAR-T in pets is regulated by USDA, not FDA, thus we can get to market 2-3x faster and for 500x less capital than human CAR-T", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/wesley-wierson", "x_url": "https://www.twitter.com/dna4cy", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/8f1452b8b0f4c51e048283655f5bf6dd88481a83.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 26311, "name": "WhiteLab Genomics", "slug": "whitelab-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ba69864f65b85fda9f05c3280bc3b39f42500013.png", "website": "https://whitelabgx.com", "all_locations": "Paris, Île-de-France, France", "long_description": "WhiteLab Genomics is a TechBio company using artificial intelligence to design the building blocks of genomic medicines. Its proprietary ALFRED platform designs viral and non-viral delivery vehicles and programmable genetic payloads, which are then experimentally validated and tested in vivo to identify candidates with the properties required for therapeutic development. \r\n\r\nThrough this integrated approach, WhiteLab Genomics is building a portfolio of validated bio-assets that it advances independently and with pharmaceutical and biotechnology partners developing the next generation of genomic medicines.\r\n\r\nFounded in 2019, WhiteLab works with industrial and academic partners including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris and the Paris Brain Institute, alongside additional collaborations with biotechnology companies. The company is part of Y-Combinator, Station F and Future4Care and is a French Tech 2030 laureate.\r\n\r\nWhiteLab Genomics operates from Paris, Boston, and Montreal.", "one_liner": "Unleash the potential of genomic medicine using AI", "team_size": 52, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1644584538, "tags": [ "Gene Therapy", "Cell Therapy", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "France", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/whitelab-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/whitelab-genomics.json", "year_founded": 2019, "city": "Paris", "country": "FR", "linkedin_url": "https://www.linkedin.com/company/whitelabgenomics/", "x_url": "https://twitter.com/whitelabg?lang=en", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ba69864f65b85fda9f05c3280bc3b39f42500013.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Nicolas Dessaigne", "url": "https://www.ycombinator.com/people/nicolas-dessaigne" }, "founders": [ { "user_id": 818146, "full_name": "David Delbourgo", "title": "Founder", "founder_bio": "23 y of experience in healthcare innovation with multiple executive roles in Business Development, Marketing and Commercial Operations.\nFormer GE Healthcare. MBA Chicago Booth, Biomedical Engineer MS University of Compiègne, France.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/daviddelbourgo/", "x_url": "https://twitter.com/DavidDelBourgo", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c81c5cf739a324b1b2c85449e1553e6b4e509e6b.jpg" }, { "user_id": 847212, "full_name": "Julien Cottineau", "title": "Founder", "founder_bio": "Senior application scientist at Genomic Vision, leading provider of genetic devices and platform\nResearch fellow at Rockefeller Univ & Necker Hospital on human complex immune deficiencies in J-L Casanova’s lab\nPhD in genetics, molecular biology & immunology at Université Pierre & Marie Curie\u000bWith Honors\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/julien-cottineau-8a8b65112/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e08d2afde8df9bb0f1975eb86f59b18a4ac2afa3.jpg" } ], "jobs": [], "news": [ { "title": "How WhiteLab Genomics is using AI to aid gene and cell therapy development • TechCrunch", "url": "https://techcrunch.com/2022/09/12/how-whitelab-genomics-is-using-ai-to-aid-gene-and-cell-therapy-development/", "date": "Sep 12, 2022" } ], "launches": [] }, { "id": 26427, "name": "Eugit Therapeutics", "slug": "eugit-therapeutics", "former_names": [ "EUGIT Tx", "EUGIT Therapeutics", "Eugit", "Eugit Therapeutics Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "website": "http://www.eugittx.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\r\n\r\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).", "one_liner": "Enabling Tissue Targeting of Therapies", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656718658, "tags": [ "Cell Therapy", "Synthetic Biology", "Therapeutics", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/eugit-therapeutics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/eugit-therapeutics.json", "year_founded": 2022, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/eugit", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 588526, "full_name": "Nizar Batada", "title": "Founder/CEO", "founder_bio": "Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.", "is_active": true, "linkedin_url": "https://linkedin.com/in/nizar-batada", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/aa4ec5a091a22bc8ded999621c25385540ddb3cb.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 64275, "title": "EUGIT Therapeutics – Next generation T cell based cancer immunotherapy", "tagline": "Engineered gamma delta T-cells for off-the-shelf treatment of cancers", "body": "We are a therapeutics company that is developing immune cell based therapy for treatment of breast, ovarian and prostate cancers.\n\n**Problem**\n\nCancer remains an unsolved problem – it is expected that 1.8M new cancer cases and 0.6M cancer deaths will occur this year in the US (source CDC). Although development of immunotherapies such as checkpoint inhibitors and CAR-T cells have shown remarkable clinical success, they work for only a few cancer types. In particular, they do not work for some of the most common types of cancers in women (breast and ovarian) and men (prostate).\n\n**Solution**\n\nBuilding upon the discoveries of the founders, EUGIT Therapeutics is engineering cancer-fighting immune cells known as the gamma delta T cells which overcome the limitations of existing cancer immunotherapies.\n\n**How it works**\n\nWe take blood from healthy donors and isolate a specific type of immune cell called the gamma delta T cell and then endow them with cancer fighting activity via gene engineering. Our engineered T cells can be used off-the-shelf and ready for infusion into cancer patients.\n\n![uploaded image](/media/?type=post&id=64275&key=user_uploads/588526/a5ffcb03-a060-4080-9d9b-df2e92e6e72f)\n\n**Founders**\n\n[George Church](https://www.linkedin.com/in/george-church-2b86301/) (Co-Founder and Scientific Advisor): George is a Professor of Genetics at Harvard Medical School and leads Synthetic Biology at the Wyss Institute. His innovations have contributed to nearly all \"next generation\" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ). \n\n[Nizar Batada](https://www.linkedin.com/in/nizar-batada/) (Co-Founder and CEO): Nizar is a cancer biologist with over 20 years of experience working in genomics and cancer research. He did his PhD at Stanford and postdoc with George Church. Previously, he was a tenure track group leader at the University of Edinburgh where he directed a research lab that focused on cancer immunology. Before founding EUGIT therapeutics, he was a senior scientist at 23andMe’s Therapeutics division. The current work he is pursuing at EUGIT therapeutics is based on his discovery of a subtype of tumor infiltrating gamma delta T cells that are associated with good clinical outcomes in breast cancer. ", "url": "https://www.ycombinator.com/launches/Gih-eugit-therapeutics-next-generation-t-cell-based-cancer-immunotherapy", "votes": 20, "created_at": "2022-07-01T19:56:00.640Z" } ] }, { "id": 28205, "name": "Modulari-T", "slug": "modulari-t", "former_names": [ "Modulari-T Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "website": "https://modularit.bio", "all_locations": "Montreal, QC, Canada; San Francisco, CA, USA", "long_description": "Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\r\n\r\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\r\n\r\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.", "one_liner": "We teach your immune system to attack and cure cancer", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1675126815, "tags": [ "Gene Therapy", "Cell Therapy", "Synthetic Biology", "Biotech", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Canada", "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/modulari-t", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/modulari-t.json", "year_founded": 2021, "city": "Montreal", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/modulari-t-bio/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1049972, "full_name": "David White", "title": "Founder", "founder_bio": "David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology.\n\nDuring his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T.\n\nWhen he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/david-white-modulari-t/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/02ce0c5af1e07f18b7b09b99212309d6f1df723e.jpg" }, { "user_id": 1161771, "full_name": "Stephanie Mok", "title": "Founder", "founder_bio": "Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk \"Lessons learned and mistakes made growing the world's hottest peppers\".", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/stephmok/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7e84b9438e87a1adf29d92d2525871a030ab8753.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 68886, "title": "Modulari-T 🧬 Unleash the full power of the immune system", "tagline": "We teach your immune system to attack and cure cancer.", "body": "# Modulari-T AWAY!\n\nHi YC, this is [@David](https://www.linkedin.com/in/david-white-modulari-t/) and [@Stephanie](https://www.linkedin.com/in/stephmok/) from [@Modulari-T](https://www.linkedin.com/company/modulari-t-bio/) launching!\n\n### **WHAT WE DO**\n\nModulari-T is a cell therapy company that can teach your immune system to attack and cure cancer.\n\n \n\nWe are a dynamic group of scientists bringing together protein engineering, synthetic biology, and immunology to create the world’s most powerful cell programming platform.\n\n \n\nBy introducing our optimized gene sequences inside immune cells, we can create treatments that are 2x potent as chemotherapy, but that avoids 90% of harmful side-effects.\n\n \n\nToday, cell therapy has a high failure rate and is difficult to produce, leaving 20M patients without hope. Modulari-T has the technology to fix this, bring hope to cancer patients, and supercharge the cell therapy market to grow beyond $50B by the end of the decade.\n\n \n\n### **HOW YOU CAN HELP**\n\nConnect us with people in the ecosystem! Do you know anyone working in cell therapy or oncology? We want to talk to them, to know about their pain points - academic, biotech/pharma or physicians.\n\n[We are hiring!](https://modulari-t.breezy.hr/) Are you a synthetic biologist or immunologist? Ready to join a new adventure? Become part of the Modulari-T squad (Mod Squad!) in beautiful Montreal!\n\n### **THE SCIENCE**:\n\nWe have built a platform to produce a new type of receptor, the Modular Actuation Receptor Complex or MARC, that mimics the modular architecture of immune receptors. These receptors can be used to reprogram immune cells to recognize cancer antigens and direct an immune response against tumor cells. Compared to CAR-T cells, MARCs have twice the tumor clearing power and avoid causing immune exhaustion to ensure a long lasting response.\n\n![](https://lh6.googleusercontent.com/ItKO7egaIuynMGKcNjoT2YMqkANZ6E6oNxe5RyIisJ47KOaWhchZU9NpFHXfqkGu_EIB6--huJ4KOnT_5IqHMQut2czid5T8krpDXcZ3iSYTSEL9y2tyAg2IfOYSLic_Uaiz7dOJbcH6dELlc-MPEA)\n\nThe MARC’s unique architecture allows us to link any extracellular cue with the required signalling outputs across different pathways to achieve therapeutic success.\n\n![uploaded image](/media/?type=post&id=68886&key=user_uploads/1161771/abbed6b1-a7be-43e4-821c-8daa69fff47a)\n\nOncology is only the first step; the MARC platform is applicable to autoimmunity, neurology, regenerative medicine and more!\n\n### **HOW WE CAN HELP YOU**\n\nAre you a Cell Therapy company? Let us show you how Modulari-T’s MARC platform can help your development. Our platform can do anything but we can’t do everything alone. That’s why we want to partner with you and bring hope to as many patients as we can.\n\n### Thank you!\n\n![uploaded image](/media/?type=post&id=68886&key=user_uploads/1161771/773beb5d-3dbb-4905-8b5e-c5e453a33517)\n\n", "url": "https://www.ycombinator.com/launches/Hv4-modulari-t-unleash-the-full-power-of-the-immune-system", "votes": 863, "created_at": "2023-01-31T18:07:52.539Z" } ] } ]